Compare CSV & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSV | ACRS |
|---|---|---|
| Founded | 1991 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 643.0M | 608.9M |
| IPO Year | 1996 | 2015 |
| Metric | CSV | ACRS |
|---|---|---|
| Price | $37.88 | $5.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $59.00 | $10.20 |
| AVG Volume (30 Days) | 125.5K | ★ 2.0M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.92% | N/A |
| EPS Growth | 54.76 | ★ 69.01 |
| EPS | ★ 0.84 | N/A |
| Revenue | ★ $417,440,000.00 | $1,683,000.00 |
| Revenue This Year | $7.35 | N/A |
| Revenue Next Year | $3.87 | $4.24 |
| P/E Ratio | $45.32 | ★ N/A |
| Revenue Growth | ★ 3.28 | N/A |
| 52 Week Low | $37.11 | $1.46 |
| 52 Week High | $52.10 | $5.85 |
| Indicator | CSV | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 41.74 | 65.27 |
| Support Level | $37.13 | $4.13 |
| Resistance Level | $44.62 | N/A |
| Average True Range (ATR) | 1.13 | 0.31 |
| MACD | 0.17 | 0.06 |
| Stochastic Oscillator | 28.42 | 77.41 |
Carriage Services Inc is a provider of funeral and cemetery services and merchandise in the United States. It operates in two business segments: The Funeral Home Operations segment offers burial, cremation, and consultation services; removes and prepares remains; sells caskets, urns, and related funeral merchandise. The company enables the use of funeral home facilities for visitation, remembrance, and transportation services. The Cemetery Operations segment provides services, such as mausoleum spaces and niches, private estates, lawn crypt gardens, traditional single burial gravesites, and burial vaults. The majority of revenue is derived from The Funeral Home Operations segment.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.